# Anthropic 计划 9 月或 10 月 IPO，投资者担忧中国竞品与政治阻力

- 来源：The Decoder：AI News（RSS）
- 作者：Maximilian Schreiner
- 发布时间：2026-08-11 20:49
- AIHOT 分数：65
- AIHOT 链接：https://aihot.virxact.com/items/cmsooqmrn07perop25514ksez
- 原文链接：https://the-decoder.com/anthropics-planned-mega-ipo-faces-investor-skepticism-over-chinese-rivals-and-political-headwinds

## AI 摘要

Anthropic 正筹备 9 月或 10 月的 IPO，当前估值 9650 亿美元，或为整个 AI 行业估值定下基准。初步会议中，投资者就中国低价 AI 模型、与特朗普政府的关系及数据中心建设阻力提出质疑。Anthropic 淡化中国竞争，强调专注顶级模型，并计划通过健康和生物学应用应对负面舆论；其 5 月年化收入已超 470 亿美元。

## 正文

Key Points

Anthropic is planning an IPO for September or October that, at a current valuation of $965 billion, will likely set the benchmark for how the entire AI industry gets valued.

During preliminary meetings, potential investors have raised concerns about cheaper AI models from China, political tensions with the Trump administration, and pushback against building new data centers.

The company is downplaying Chinese competition, pointing to its focus on top-tier models, and plans to counter negative public sentiment with new applications in health and biology.

Anthropic is targeting a September or early October IPO and is already meeting with potential investors. According to the Wall Street Journal, those investors are asking tough questions about cheap Chinese models, the Trump administration, and resistance to data center construction.

Anthropic is gearing up for what could be the largest IPO ever, and the pitch is getting harder. According to a Wall Street Journal report, the company, currently valued at $965 billion, is meeting with potential investors and pointing to its growth rate along with strategies for countering growing public backlash against AI. The company is aiming for a debut in September or early October but hasn't shared pricing expectations or an exact timeline yet.

During preliminary meetings over the past few weeks, investors have pressed Anthropic's leadership on three topics: the popularity of cheaper AI systems from China, tensions with the Trump administration, and pushback against building data centers in the US. In each case, the question was the same: what does this mean for growth?

Anthropic has been downplaying the Chinese competition, according to the report, stressing that it's focused solely on top-tier models. CEO Dario Amodei and other senior US executives have publicly argued that most users want the smartest system available at any given time, and that Chinese models typically trail the best Western models by at least a few months.

That argument is under pressure, though. With Kimi K3 and Qwen3.8, Chinese models have recently closed much of the gap with Western frontier models. Across many benchmarks, the six-to-eight-month lead that executives once claimed looks much smaller now. For a company whose valuation rests on a technology advantage, that's a real problem. To counter negative sentiment around AI, Anthropic plans to push harder into health and biology applications, according to people involved in the discussions.

Anthropic's IPO price will set the bar for the entire AI industry

The price Anthropic sets and how the stock performs after listing will shape how investors value leading AI developers going forward. Trillions in AI spending, mostly on compute, rest on the assumption that demand keeps climbing steeply. SpaceX serves as a cautionary tale: The company topped a $2 trillion valuation after its IPO this year but gave back a big chunk of those gains after the initial spike. Some bullish analysts expect Anthropic to surpass that mark.

On the business side, Anthropic pulled ahead of rivals earlier this year on the strength of its coding tool Claude Code, according to the report. In May, the company pegged its annualized revenue at over $47 billion. Usage data still shows strong demand, though the service has also seen repeated outages this year. Over the past few weeks, Anthropic signed several new compute contracts, including deals with SpaceX and Google. Its main rival OpenAI is expected to follow with its own IPO, possibly not until next year.

WSJ